Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Reata

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

CHMP recommends Travere and CSL Vifor’s Filspari to treat rare kidney disease IgAN

The rare form of kidney disease is estimated to affect around 25 per million adults worldwide

- PMLiVE

NICE recommends STADA and Calliditas’ Kinpeygo to treat rare kidney disease IgAN

Affecting approximately 14,000 in England, IgA nephropathy occurs when IgA accumulates in the kidneys, causing inflammation and scarring

- PMLiVE

Novartis shares positive phase 3 results for atrasentan in rare kidney disease

The company gained access to the candidate after it acquired Chinook Therapeutics

- PMLiVE

Novartis to acquire Chinook Therapeutics for approximately $3.5bn

The deal marks a notable expansion to the Swiss drugmaker's kidney disease pipeline

- PMLiVE

New research shows potential to treat kidney disease with common medicines

Acute kidney injuries cause around 20% of all emergency hospital admissions in the UK

Cannes Lion 2022

Our Top 5 Pharma Picks From Cannes Lions

Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022.

The Good Ideas Group

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

Moving Away from Hospital-Centered Care: Barriers & Opportunities

David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips...

Impetus Digital

- PMLiVE

Evotec and Vifor announce joint venture for kidney disease treatments

Both companies will split the clinical and commercial costs equally

Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney disease

Treatment can help patients with advanced disease, companies say

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links